CDC issues global dengue travel notice as Americas surge

The US Centers for Disease Control and Prevention has updated its global travel notice for dengue after sustained outbreaks across the Americas, expanding its guidance for international travelers as the mosquito-borne virus continues to drive millions of infections and renewed concern in popular tourism destinations.

Global dengue travel notice updated for 2026

The CDC’s Travelers’ Health page now lists a Level 1 Global Dengue notice, refreshed on November 10, 2026, advising travelers to practice usual precautions in countries reporting higher than expected dengue activity, including several in Latin America and the Caribbean that are key winter-sun markets for North American visitors.

Publicly available CDC information describes dengue as a year-round risk in many tropical and subtropical regions, with outbreaks that tend to spike every two to five years. The current notice groups multiple affected destinations under a single global advisory instead of issuing a series of country-by-country alerts, reflecting the scale and geographic spread of recent transmission.

CDC’s dengue risk pages highlight that parts of South America, Central America, Mexico and the Caribbean remain areas with active dengue transmission. As of early November 2026, Cuba, for example, meets the criteria for high transmission and has reported at least 10 dengue cases among returning US travelers in the previous three months, a benchmark CDC uses when deciding whether to feature a country in its notices.

The Level 1 classification does not advise canceling trips. Instead, it stresses awareness of dengue risk, personal protection against mosquito bites and prompt medical evaluation for travelers who develop compatible symptoms during or after travel.

Record outbreaks in the Americas underpin CDC’s move

The updated travel notice follows several years of unprecedented dengue activity in the region. Data from the Pan American Health Organization show that countries in the Americas reported more than 13 million dengue cases in 2024, the highest number since regional records began in 1980 and roughly triple the total seen in 2023.

Although reported cases declined in 2025, with around 4.5 million suspected infections across the Americas, transmission remained well above the historical average. PAHO situation reports describe 2024 as a turning point, with at least 23 countries simultaneously facing large outbreaks, straining health services and vector control programs in major cities and secondary destinations alike.

Recent analytical reviews of the dengue situation in the Americas note that all four dengue virus serotypes are now circulating in several countries, a pattern that increases the risk of severe illness among people who have been infected in the past. The same publications highlight that travel-associated cases surged alongside local outbreaks, including in the continental United States, where Florida, California and Texas all reported locally acquired dengue in 2024.

Travel medicine briefings from US state and academic centers emphasize that this sustained, multi-year elevation in transmission is a key driver behind global travel notices. With high-volume air links connecting US hubs to Caribbean islands, Mexican beach resorts and South American capitals, travelers are an important bridge for dengue movement in and out of the region.

Understanding the “brain-bleed” headlines around dengue

Some recent media coverage has used dramatic language for dengue, referring to it as an “incurable brain-bleed virus.” Medical references describe dengue as a viral infection transmitted by Aedes mosquitoes that typically causes high fever, headache, muscle and joint pain, rash and marked fatigue. Most infections are mild or even asymptomatic and resolve with supportive care.

Severe dengue, previously known as dengue hemorrhagic fever and dengue shock syndrome, can involve bleeding, plasma leakage and organ impairment. Clinical guidance explains that serious bleeding into the gastrointestinal tract or, less commonly, the brain can occur, particularly in people experiencing a second infection with a different serotype, or in those with certain underlying conditions. These complications are relatively rare compared with the total number of infections, but they are the main cause of dengue-related deaths.

There is currently no widely available antiviral cure for dengue, and vaccines remain limited in availability and eligibility. Because of this, prevention focuses on avoiding mosquito bites and seeking early medical care for warning signs such as severe abdominal pain, persistent vomiting, rapid breathing, bleeding from the gums or nose, or unusual drowsiness or confusion. Travel health agencies underline that early diagnosis and careful fluid management in health facilities significantly reduce the risk of fatal outcomes.

For travelers, the key takeaway is that while dengue can in rare cases lead to severe bleeding, including into the brain, that outcome represents a small fraction of overall cases. The heightened language in some headlines contrasts with the more measured tone of official travel and clinical guidance, which encourages informed caution rather than alarm.

What the notice means for travelers to the Americas

The Level 1 Global Dengue notice signals that dengue is circulating widely but does not automatically trigger restrictions on tourism, flights or cruises. Air and sea links between the United States and Latin American and Caribbean destinations remain open, and travel providers continue to promote winter and spring itineraries across the region.

CDC materials emphasize that anyone who lives in or travels to an area with dengue risk can be infected, regardless of age. However, travelers with a history of prior dengue infection, certain chronic illnesses, pregnancy or very young children in their group may wish to discuss plans with a health professional before departure, particularly if heading to destinations with high or rising case counts.

Travel health guidance recommends several concrete steps for visitors: use insect repellent containing DEET, picaridin or other EPA-registered ingredients; choose accommodations with air conditioning or effective screens; wear long sleeves and trousers in areas where mosquitoes are active; and reduce standing water around villas, rental homes or campsites where mosquitoes might breed.

US public health documents also note that many dengue infections are linked to day-biting mosquitoes that thrive in urban neighborhoods, coastal resorts and small towns rather than in remote jungle areas alone. Travelers who spend long periods outdoors, such as on city walking tours, outdoor markets or beach-front patios, should apply repellent consistently, even if they are not near visible swamps or wetlands.

Monitoring destinations as case patterns shift

The CDC’s dengue pages state that countries can move between risk categories as their epidemiological situation changes, including when traveler-imported cases to the United States rise above the agency’s thresholds. In practice, this means that destinations in the Americas may appear or disappear from dengue-related travel notices over the course of a year.

Recent Spanish and English language updates on CDC and PAHO platforms describe how Cuba currently qualifies as a high-transmission setting, while other countries in the region are experiencing more moderate levels after the record-breaking 2024 season. Nonetheless, both organizations continue to frame dengue as a persistent threat across the Americas, requiring long-term investment in mosquito control, surveillance and clinical training.

For individual travelers, monitoring official travel health pages in the weeks before departure can provide a more precise picture of where dengue activity is highest at that moment. Some national public health agencies in Latin America and the Caribbean publish weekly dengue bulletins with city or province-level breakdowns, which can help trip planners understand whether their specific resort area or cruise port has recently seen an uptick in cases.

As the northern hemisphere winter travel period approaches, the combination of updated CDC guidance, ongoing PAHO alerts and continued air connectivity between the United States and the Americas suggests that dengue will remain a prominent consideration for travelers in late 2026. With no cure and limited vaccine coverage, basic mosquito protection and situational awareness remain the main tools for reducing risk while continuing to visit the region’s beaches, cities and natural attractions.